DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
Sign Up to like & getrecommendations! Published in 2018 at "Molecular cell"
DOI: 10.1016/j.molcel.2018.06.036
Abstract: The bromodomain and extra-terminal domain (BET) protein BRD4 is emerging as a promising anticancer therapeutic target. However, resistance to BET inhibitors often occurs, and it has been linked to aberrant degradation of BRD4 protein in… read more here.
Keywords: cancer; dub3; inhibitor resistance; bet inhibitor ... See more keywords
Physachenolide C is a Potent, Selective BET Inhibitor.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c01770
Abstract: A pulldown using a biotinylated natural product of interest in the 17β-hydroxywithanolide (17-BHW) class, physachenolide C (PCC), identified the bromodomain and extra-terminal domain (BET) family of proteins (BRD2, BRD3, and BRD4), readers of acetyl-lysine modifications… read more here.
Keywords: bet inhibitor; physachenolide potent; brd3 brd4; bet ... See more keywords
Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0266966
Abstract: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and poor prognosis. Emerging evidence suggests that epigenetic alterations play a crucial role in HCC, suggesting epigenetic inhibition as a promising therapeutic approach. Indeed, the… read more here.
Keywords: transcriptome profiling; treated hepg2; inhibitor treated; comprehensive transcriptome ... See more keywords
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML
Sign Up to like & getrecommendations! Published in 2022 at "In Vivo"
DOI: 10.21873/invivo.12872
Abstract: Background/Aim: The therapeutic potential of bromodomain and extra-terminal motif (BET) inhibitors in hematological cancers has been well established in preclinical and early-stage clinical trials, although as of yet, no BETtargeting agent has achieved approval. To… read more here.
Keywords: bet; mivebresib abbv; abbv 075; clinical modeling ... See more keywords
BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cancer"
DOI: 10.7150/jca.69375
Abstract: Most colorectal cancer (CRC) patients are insensitive to immune checkpoint inhibitors (ICIs) due to the immunosuppressive tumor microenvironment (TME). Epigenetic factors such as the bromo-and extraterminal domain (BET) family proteins may be responsible for the… read more here.
Keywords: tumor immunity; anti tumor; crc; bet inhibitor ... See more keywords